We are thrilled to share a major milestone in Technophage’s TP-102 clinical trial – REVERSE 2 – with the Last Patient First Visit (LPFV) now completed.This achievement reflects the dedication of our local teams and, most importantly, the commitment of every patient who has taken part. With all patients in India having completed treatment and follow-up, the US is now entering the final phase: treating the last patients and completing recruitment.
For those eagerly awaiting results, this strong completion rate highlights the significant progress we have made and opens doors to further advancing the clinical development of TP-102. A heartfelt thank you to our clinical teams, investigators, patients, and partners. Your dedication is bringing us closer to the finish line.
Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102
